Shanna Fuld

About the Author Shanna Fuld

Shanna J. Fuld is a journalist specializing in finance. Born and raised in Queens, New York, she’s been avoiding dates with finance guys for years – only to find herself becoming one. The former NY1er worked as a videographer, assignment editor and writer for the beloved local news channel before joining the Smarter Analyst team.

Is Advanced Micro Devices (AMD) All Smoke & Mirrors?

Overrated and not what it seems. That’s what blogger Okapi Research (OR) says Advanced Micro Devices (AMD) stock is.

Is Micron (MU) Stock Doing as Poorly as Wall Street Makes it Out to Be?

Micron (MU) stock has been victim to a whirlwind of issues in the stock market. There’s an oversupply of inventory, pricing pressures, a …

Global Blood Therapeutics (GBT) Gets Attention of FDA As Well As Investors

Monday morning Global Blood Therapeutics (GBT) announced the FDA has agreed to GBT’s plan to file for accelerated approval of voxelotor, a unique …

Tigress Top Analyst Explains Why Investors Should Snatch Up Amazon (AMZN) Stock While It’s Low

While many investors are pulling out of Amazon (AMZN) stock, Tigress Financial’s Ivan Feinseth is going in. He sees this moment as an …

Analyst Predicts Success for Catalyst Pharmaceutical (CPRX ) Stock Following News of Latest FDA Approval

Catalyst Pharmaceutical (CPRX) stock fell about 8% between Thursday and Friday. Even though the company just announced its first FDA approval for Firdapse, …

Cowen Analyst Goes All in For Vertex (VRTX) Stock

Vertex (VRTX) is Cowen analyst’s top large-cap pick for the second year in a row. That’s how Phil Nadeau put it while increasing …

What New Information is Causing This Bull to Charge Ahead for Amarin (AMRN) Stock?

The Amarin (AMRN) saga is not over yet. Following a somewhat dramatic couple of weeks after the release of the biopharmaceutical’s drug, Vascepa, analysts …

Analyst Doubles Down on Low Estimates for Micron (MU) Stock

Susquehanna analyst Mehdi Hosseini is still Neutral on Micron Technology (MU) stock and says he feels comfortable with his below-consensus estimates for the …

Top Analyst Stands Firm for Acadia Pharmaceutical (ACAD) Stock While its Anti-Depression Medication Goes Through Trial

After a series of talks with depression key opinion leaders (KOL) about Acadia Pharmaceutical’s (ACAD) Ph2 CLARITY trial, all four experts believe the …

In the World of Emerging Electric Cars — Will Tesla (TSLA) Be the First and the Last Company Standing?

In a recent post from blogger Sapient Investor, the writer discusses what Tesla (TSLA) has brought to the table and what is in …